—
Enter label dose
Trial reference
From your label
Enter your label dose — the gauge updates instantly.
Seven-RCT meta-analysis in postmenopausal women found +0.37 kg lean mass (95% CI +0.05 to +0.69). Most included trials used ≥5 g/day with resistance training; 3 g/day is a common maintenance floor.
Educational only — not medical advice. Disclaimer.
NIH DSLD market slice
Bulk CSV dump 16 January 2026 · label entries through 2025. Disclosed amounts only — proprietary blends without gram weights excluded.
Trial floors
Primary
Maintenance (postmenopausal + training meta-analyses) · 3–5 g · Benefit shown — Seven-RCT meta-analysis in postmenopausal women found +0.37 kg lean mass (95% CI +0.05 to +0.69). Most included trials used ≥5 g/day with resistance training; 3 g/day is a common maintenance floor.
Secondary
Two-year bone trial dose (research) · 0.14 g/kg over 2 years · Primary endpoint missed — ~8–10 g at 60 kg. The primary endpoint failed — no effect on femoral neck, total hip or lumbar spine bone density over two years. Only secondary femoral-neck geometry (section modulus, buckling ratio) favoured creatine. This is a dose reference, not evidence that creatine builds bone.
Label reading notes
- Evidence-backed maintenance is creatine monohydrate with grams listed per serving. Micronized monohydrate is the same molecule; proprietary "buffers" and blends are not required for the trials cited here.
- Third-party tested monohydrate (NSF, Informed Sport, USP where available) reduces contamination risk; the dose math still has to reach 3–5 g/day for typical training use.
- Loading (~20 g/day × 5–7 days) saturates faster but is optional. Many people reach saturation on 3–5 g/day without a loading phase.
- Serum creatinine may rise on creatine without kidney injury — tell your clinician before routine labs so a training-related bump is not misread.

